Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
Facon, Thierry, Kumar, Shaji, Plesner, Torben, Orlowski, Robert Z, Moreau, Philippe, Bahlis, Nizar, Basu, Supratik, Nahi, Hareth, Hulin, Cyrille, Quach, Hang, Goldschmidt, Hartmut, O’Dwyer, Michael, Perrot, Aurore, Venner, Christopher P, Weisel, Katja, Mace, Joseph R, Raje, Noopur, Attal, Michel, Tiab, Mourad, Macro, Margaret, Frenzel, Laurent, Leleu, Xavier, Ahmadi, Tahamtan, Chiu, Christopher, Wang, Jianping, Van Rampelbergh, Rian, Uhlar, Clarissa M, Kobos, Rachel, Qi, Ming, Usmani, Saad Z
Published in The New England journal of medicine (30.05.2019)
Published in The New England journal of medicine (30.05.2019)
Get full text
Journal Article
Real-world effectiveness of ixazomib combined with lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: the REMIX study
Macro, M., Hulin, C., Vincent, L., Charvet-Rumpler, A., Benboubker, L., Calmettes, C., Stoppa, A.-M., Laribi, K., Clement-Filliatre, L., Zerazhi, H., Honeyman, F., Richez, V., Maloisel, F., Karlin, L., Barrak, J., Chouaid, C., Leleu, X.
Published in Annals of hematology (01.08.2023)
Published in Annals of hematology (01.08.2023)
Get full text
Journal Article
Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone
Avet-Loiseau, H, Soulier, J, Fermand, J-P, Yakoub-Agha, I, Attal, M, Hulin, C, Garderet, L, Belhadj, K, Dorvaux, V, Minvielle, S, Moreau, P
Published in Leukemia (01.03.2010)
Published in Leukemia (01.03.2010)
Get full text
Journal Article
Minor clone provides a reservoir for relapse in multiple myeloma
Magrangeas, F, Avet-Loiseau, H, Gouraud, W, Lodé, L, Decaux, O, Godmer, P, Garderet, L, Voillat, L, Facon, T, Stoppa, A M, Marit, G, Hulin, C, Casassus, P, Tiab, M, Voog, E, Randriamalala, E, Anderson, K C, Moreau, P, Munshi, N C, Minvielle, S
Published in Leukemia (01.02.2013)
Published in Leukemia (01.02.2013)
Get full text
Journal Article
Deletion of the 1p32 region is a major independent prognostic factor in young patients with myeloma: the IFM experience on 1195 patients
Hebraud, B, Leleu, X, Lauwers-Cances, V, Roussel, M, Caillot, D, Marit, G, Karlin, L, Hulin, C, Gentil, C, Guilhot, F, Garderet, L, Lamy, T, Brechignac, S, Pegourie, B, Jaubert, J, Dib, M, Stoppa, A-M, Sebban, C, Fohrer, C, Fontan, J, Fruchart, C, Macro, M, Orsini-Piocelle, F, Lepeu, G, Sohn, C, Corre, J, Facon, T, Moreau, P, Attal, M, Avet-Loiseau, H
Published in Leukemia (01.03.2014)
Published in Leukemia (01.03.2014)
Get full text
Journal Article
Real-Life Management of Patients Aged 80 Years Old and Over With Multiple Myeloma: Results of the EMMY Cohort
Chalopin, T., Macro, M., Decaux, O., Royer, B., Gounot, R., Bobin, A., Karlin, L., Mohty, M., Frenzel, L., Perrot, A., Manier, S., Vincent, L., Dib, M., Slama, B., Richez, V., Allangba, O., Zunic, P., Newinger-Porte, M., Mariette, C., Joly, B., Gay, J., Botoc, I., Malfuson, JV, Garlantezec, R., Hulin, C.
Published in Clinical lymphoma, myeloma and leukemia (30.09.2024)
Published in Clinical lymphoma, myeloma and leukemia (30.09.2024)
Get full text
Journal Article
Cytogenetic and therapeutic characterization of primary plasma cell leukemia: the IFM experience
Avet-Loiseau, H, Roussel, M, Campion, L, Leleu, X, Marit, G, Jardel, H, Dib, M, Decaux, O, Lamy, T, Tiab, M, Cony-Makhoul, P, Banos, A, Lepeu, G, Lifermann, F, Macro, M, Kolb, B, Hulin, C, Caillot, D, Traulle, C, Mathiot, C, Royer, B
Published in Leukemia (01.01.2012)
Published in Leukemia (01.01.2012)
Get full text
Journal Article
Safety of thalidomide in newly diagnosed elderly myeloma patients: a meta-analysis of data from individual patients in six randomized trials
Palumbo, Antonio, Waage, Anders, Hulin, Cyrille, Beksac, Meral, Zweegman, Sonja, Gay, Francesca, Gimsing, Peter, Leleu, Xavier, Wijermans, Pierre, Sucak, Gülsan, Pezzatti, Sara, Juliusson, Gunnar, Pégourié, Brigitte, Schaafsma, Martijn, Galli, Monica, Turesson, Ingemar, Kolb, Brigitte, van der Holt, Bronno, Baldi, Ileana, Rolke, Jürgen, Ciccone, Giovannino, Wetterwald, Marc, Lokhorst, Henk, Boccadoro, Mario, Rodon, Philippe, Sonneveld, Pieter
Published in Haematologica (Roma) (01.01.2013)
Published in Haematologica (Roma) (01.01.2013)
Get full text
Journal Article
Phase I study of the anti insulin-like growth factor 1 receptor (IGF-1R) monoclonal antibody, AVE1642, as single agent and in combination with bortezomib in patients with relapsed multiple myeloma
Moreau, P, Cavallo, F, Leleu, X, Hulin, C, Amiot, M, Descamps, G, Facon, T, Boccadoro, M, Mignard, D, Harousseau, J L
Published in Leukemia (01.05.2011)
Published in Leukemia (01.05.2011)
Get full text
Journal Article
Antecedents and consequences of sexual harassment in organizations: a test of an integrated model
Fitzgerald, L F, Drasgow, F, Hulin, C L, Gelfand, M J, Magley, V J
Published in Journal of applied psychology (01.08.1997)
Published in Journal of applied psychology (01.08.1997)
Get more information
Journal Article
P30 SINGLE COHORT RESULTS FROM MAJESTEC‐2: TECLISTAMAB (TEC) IN COMBINATION WITH SUBCUTANEOUS DARATUMUMAB (DARA) AND LENALIDOMIDE (LEN) IN PATIENTS WITH MULTIPLE MYELOMA (MM)
Searle, E., Quach, H., Wong, S., Costa, L., Hulin, C., Janowski, W., Berdeja, J., Anguille, S., Matous, J., Touzeau, C., Michallet, A., Husnik, M., Vishwamitra, D., Niu, Z., Larsen, J., Chen, L., Goldberg, J., Popat, R., Spencer, A.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
S176: DARATUMUMAB CARFILZOMIB LENALIDOMIDE AND DEXAMETHASONE AS INDUCTION THERAPY IN HIGH‐RISK TRANSPLANT ELIGIBLE NEWLY DIAGNOSED MYELOMA PATIENTS: RESULTS OF THE PHASE 2 STUDY IFM 2018‐04
Touzeau, C., Perrrot, A., Hulin, C., Manier, S., Macro, M., Chretien, M.‐L., Karlin, L., Decaux, O., Jacquet, C., Tiab, M., Leleu, X., Planchce, L., Avet‐Loiseau, H., Moreau, P.
Published in HemaSphere (01.06.2022)
Published in HemaSphere (01.06.2022)
Get full text
Journal Article
Safe and prolonged survival with long-term exposure to pomalidomide in relapsed/refractory myeloma
Fouquet, G., Pegourie, B., Macro, M., Petillon, M.O., Karlin, L., Caillot, D., Roussel, M., Arnulf, B., Mathiot, C., Marit, G., Kolb, B., Stoppa, A.M., Brechiniac, S., Richez, V., Rodon, P., Banos, A., Wetterwald, M., Garderet, L., Royer, B., Hulin, C., Benbouker, L., Decaux, O., Escoffre-Barbe, M., Fermand, J.P., Attal, M., Avet-Loiseau, H., Moreau, P., Facon, T., Leleu, X.
Published in Annals of oncology (01.05.2016)
Published in Annals of oncology (01.05.2016)
Get full text
Journal Article
Thalidomide versus dexamethasone for the treatment of relapsed and/or refractory multiple myeloma: results from OPTIMUM, a randomized trial
KROPFF, Martin, GIONGCO BAYLON, Honorata, AVET-LOISEAU, Herve, MOEHLER, Thomas M, PATTOU, Claire, LUCY, Lela, KUEENBURG, Elisabeth, GLASMACHER, Axel, ZERBIB, Robert, FACON, Thierry, HILLENGASS, Jens, ROBAK, Tadeusz, HAJEK, Roman, LIEBISCH, Peter, GORANOV, Stefan, HULIN, Cyrille, BLADE, Joan, CARAVITA, Tommaso
Published in Haematologica (Roma) (01.05.2012)
Published in Haematologica (Roma) (01.05.2012)
Get full text
Journal Article
Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program
Damaj, G., Malard, F., Hulin, C., Caillot, D., Garidi, R., Royer, B., Marit, G., Stoppa, A.M., Banos, A., Morineau, N., Moreau, P., Fitoussi, O., Tiab, M.
Published in Leukemia & lymphoma (01.04.2012)
Published in Leukemia & lymphoma (01.04.2012)
Get full text
Journal Article
P16 HEALTH‐RELATED QUALITY OF LIFE FOR FRAIL TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED WITH DARATUMUMAB, LENALIDOMIDE AND DEXAMETHASONE: SUBGROUP ANALYSIS OF MAIA TRIAL
Facon, T., Plesner, T., Usmani, S., Kumar, S., Bahlis, N., Hulin, C., Orlowski, R., Nahi, H., Mollee, P., Ramasamy, K., Roussel, M., Jaccard, A., Delforge, M., Karlin, L., Arnulf, B., Chari, A., Pei, H., Gupta, N., Kaila, S., Matt, K., Gries, K., Carson, R., Borgsten, F., Weisel, K., Perrot, A.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
P09 DARATUMUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE (D‐RD) VERSUS LENALIDOMIDE AND DEXAMETHASONE (RD) ALONE IN TRANSPLANT‐INELIGIBLE PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM): UPDATED ANALYSIS OF THE PHASE 3 MAIA STUDY
Weisel, K., Kumar, S., Moreau, P., Bahlis, N., Facon, T., Plesner, T., Orlowski, R., Basu, S., Nahi, H., Hulin, C., Quach, H., Goldschmidt, H., O'Dwyer, M., Perrot, A., Venner, C., Raje, N., Tiab, M., Macro, M., Frenzel, L., Leleu, X., Pei, H., Krevvata, M, Carson, R, Borgsten, F., Usmani, S.
Published in HemaSphere (09.05.2023)
Published in HemaSphere (09.05.2023)
Get full text
Journal Article
P904: CILTACABTAGENE AUTOLEUCEL VS TREATMENTS FROM REAL‐WORLD CLINICAL PRACTICE FOR TRIPLE CLASS EXPOSED PATIENTS WITH MULTIPLE MYELOMA: ADJUSTED COMPARISONS BASED ON CARTITUDE‐1 AND THE EMMY FRENCH COHORT
Decaux, O., Hulin, C., Perrot, A., Macro, M., Frenzel, L., Diels, J., Perualila, N. J., Ghilotti, F., Haefliger, B., Goldsztajn, E., Vernet, S., Thevenon, J., Willaime, M., Texier, N., Schecter, J. M., Madduri, D., Jackson, C., Valluri, S., Moreau, P.
Published in HemaSphere (23.06.2022)
Published in HemaSphere (23.06.2022)
Get full text
Journal Article